Drug intelligence / Profile preview

Bacillus coagulans TCI711

Development stage: Preclinical
Lead developer: TCI
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bacillus coagulans TCI711 is a specific probiotic strain of the Gram-positive, spore-forming bacterium *Bacillus coagulans*, originally isolated from apples. Developed by TCI Co., Ltd., this strain is characterized by its ability to produce lactic acid and its high stability against heat, acid, and bile, allowing it to survive transit through the gastrointestinal tract. It is being investigated for its potential to enhance alcohol metabolism (alcohol elimination) and to improve liver function and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD). The strain's mechanism likely involves modulation of the intestinal microbiome and metabolic pathways related to ethanol and lipid processing.

Other names: Bacillus coagulans TCI711

Beyond the preview

Go deeper on Bacillus coagulans TCI711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacillus coagulans TCI711.

Explore the full profile